Precision medicine for all common diseases with the SCIOSM method
BBCR Consulting, 95 Eliot St, Natick, MA USA.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 24(03), 149–153.
Article DOI: 10.30574/gscbps.2023.24.3.0255
Publication history:
Received on 18 May 2023; revised on 01 July 2023; accepted on 04 July 2023
Abstract:
This article examines the advancements in scientific research and the challenges associated with translating them into clinical practice. To address the challenges the pharmaceutical and biotechnology industry faces, it highlights the success of innovative approaches in rare disease drug development, particularly in overcoming obstacles specific to orphan indications. More importantly, the concept of Strategic Clinical Innovation OrganizationSM (SCIO) was introduced as a method to tackle the challenges in translational medicine as it has proven effective for orphan indications and holds potential for broader application in clinical trial strategy design. It emphasizes that SCIOSM method’s integration of early clinical and regulatory strategies, non-clinical evidence, and the utilization of AI and data analytics enhances trial efficiency and optimizes trial design and execution. In addition, this article stressed the significance of SCIOSM utilizing biomarker validation in guiding precision medicine interventions and improving patient stratification and clinical trial design. Overall, the transition to precision medicine holds promise for delivering more individualized and personalized care to patients care, improving treatment outcomes, minimizing adverse events, and transforming healthcare.
Keywords:
SCIO; Strategic Clinical Innovation Organization; Clinical Strategy; Regulatory Strategy; AI; Clinical Trial Strategy; Precision Medicine.
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
